Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $34.75, for a total transaction of $278,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Tabula Rasa HealthCare Inc (TRHC) traded down $0.26 during mid-day trading on Wednesday, hitting $34.75. 228,774 shares of the company were exchanged, compared to its average volume of 195,541. Tabula Rasa HealthCare Inc has a 52-week low of $11.59 and a 52-week high of $38.23. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73. The stock has a market cap of $666.57 and a PE ratio of -204.41.
Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The company had revenue of $33.27 million during the quarter, compared to analyst estimates of $31.76 million. During the same quarter last year, the business posted $0.06 EPS. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. equities research analysts predict that Tabula Rasa HealthCare Inc will post 0.03 earnings per share for the current fiscal year.
TRHC has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $29.00 price target on shares of Tabula Rasa HealthCare in a research note on Tuesday, October 24th. Wells Fargo & Co lifted their price target on shares of Tabula Rasa HealthCare from $21.00 to $27.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. BidaskClub cut shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. Finally, Citigroup initiated coverage on shares of Tabula Rasa HealthCare in a research note on Thursday, January 4th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Tabula Rasa HealthCare presently has an average rating of “Buy” and a consensus price target of $29.78.
ILLEGAL ACTIVITY NOTICE: “Tabula Rasa HealthCare Inc (TRHC) CEO Calvin H. Knowlton Sells 8,000 Shares” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/07/tabula-rasa-healthcare-inc-trhc-ceo-calvin-h-knowlton-sells-8000-shares.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.